Kodiak Reports Positive Phase 3 Results for Two Eye Drugs
Kodiak Sciences said its experimental treatments Zenkuda and KSI501 met the primary endpoints in a Phase 3 study of wet age-related macular degeneration, prompting a sharp rise in the company’s shares. The DAYBREAK trial evaluated both candidates for the eye disease, which can cause vision loss. Kodiak said the treatments were noninferior to Eylea, a therapy made by Regeneron Pharmaceuticals, though the supplied reports do not include detailed trial data to independently assess that comparison.
The share-price figures varied by time period. Two reports said Kodiak rose about 65% in premarket trading Monday, reaching $54.42. Other accounts described a gain of about 178% over Monday’s trading session. Those figures reflect different reported periods and should not be treated as the same measurement. Shares had closed at $32.35 before the move, according to one account.
The results came from a single Phase 3 study that tested both candidates against a shared control arm, rather than from two separate trials. Kodiak said each drug achieved the study’s primary endpoint. The available accounts do not provide the effect sizes, full safety findings or statistical details needed to...